Clear Search sequence regions


  • angina (2)
  • fasudil (7)
  • phospholipid (1)
  • rats (4)
  • Sizes of these terms reflect their relevance to your search.

    The study is intended to formulate Fasudil loaded vesicular system for application in the management of angina. Fasudil was made into a complex with phospholipid, and other different formulations were made, including Fasudil solution, liposomal form, and Fasudil loaded into the gel. A drug characterization study was conducted and noted. Drug release was quantified and analyzed and, finally, inoculated in Sprague-Dawley rats. These rats underwent anginal induction, and each formulation's effect on angina was evaluated. Drug solution (F-Phos) and F-Phos-Lipo (liposomal dispersion form of the drug) have shown that more than half percent of them have been released within 1.5 hours, and the rapid release occurred from liposomal dispersion in the first hour. The study determined the viscosity of the different formulations, which was significantly (p<0.05) higher than the theoretical sum of the viscosity of each formulation. The study found that the F-Phos-Lipo+P-407HMS formulation is the most effective as its application has the minimum infarct area percentage compared to the other formulations and can also reduce creatine kinase levels significantly as compared to the different formulations (p<0.05). The study concluded that the typical gel formulation (liposomal Fasudil dispersed in hydroxypropyl methylcellulose solution, which is added to blank poloxamer 407) had been shown to have significantly anti-anginal properties, including easy administration, its application on the infarct area percentage and subsequently its pharmacological effect on the cardiac tissue.

    Citation

    A Unnisa, N E Khalifa, W M A Khojali, M E Osman, A H Alshammari, H S Alshammari, M G Alanazi, N Bandar, S B Jandrajupalli, B A Elamine, O A Mohamed, R Gangireddy. Study on development and tissue permeation of different formulations of Fasudil. European review for medical and pharmacological sciences. 2023 Jul;27(13):6393-6400

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 37458658

    View Full Text